目的 观察温针灸联合刺络拔罐治疗轻型新型冠状病毒(corona virus disease 2019,COVID-19)感染患者的临床疗效.方法 将 82 例COVID-19 轻型患者随机分为治疗组和对照组,每组 41 例.对照组予连花清瘟颗粒口服,治疗组在对照组基础上给予温针灸联合刺络拔罐治疗.比较两组退热时间,两组治疗前后咳嗽视觉模拟量表(visual analog scale,VAS)、中文版莱塞斯特咳嗽生命质量问卷(Mandarin Chinese version of the Leicester cough questionnaire,LCQ-MC)、咽干/痛缓解程度,并比较两组安全性情况,追踪观察两组患者是否出现"长新冠综合征"和COVID-19 二次感染情况.结果 两组退热时间比较差异有统计学意义(P＜0.05).两组治疗后咳嗽VAS评分低于治疗前,且治疗组低于对照组,差异有统计学意义(P＜0.05).两组治疗后LCQ-MC评分低于治疗前,且治疗组低于对照组,差异有统计学意义(P＜0.05).两组治疗后咽干/痛程度分布优于治疗前,且治疗组优于对照组,差异有统计学意义(P＜0.05).两组"长新冠综合征"发生率比较差异无统计学意义(P＞0.05).两组COVID-19 二次感染率比较差异无统计学意义(P＞0.05).两组疗法安全性均可.结论 在口服中成药的基础上,温针灸联合刺络拔罐治疗COVID-19 轻型患者在急性期临床疗效显著,安全性高.
Clinical observation of needle-warming moxibustion plus blood-letting and cupping for mild COVID-19 infection
Objective To observe the clinical efficacy of needle-warming moxibustion plus blood-letting and cupping in treating patients with mild corona virus disease(COVID)-19 infection.Method Eighty-two patients with mild COVID-19 infection were randomized into a treatment group and a control group,with 41 cases in each group.The control group was prescribed oral administration of Lian Hua Qing Wen granules,and the treatment group was additionally offered needle-warming moxibustion plus blood-letting and cupping.The defervescence time was compared between the two groups.The visual analog scale(VAS)score for cough,the score of the Mandarin Chinese version of the Leicester cough questionnaire(LCQ-MC),and the degree of dry throat/throat pain relief were compared before and after the treatment.The safety rating was also compared.The two groups were followed up to observe if there occurred"long COVID syndrome"or secondary infection of COVID-19.Result The defervescence time differed significantly between the two groups(P＜0.05).The VAS score for cough dropped in both groups after the treatment and was lower in the treatment group than in the control group,showing statistical significance(P＜0.05).After the intervention,the LCQ-MC score declined in both groups and was lower in the treatment group than in the control group,showing statistical significance(P＜0.05).The dry throat/throat pain improved after the treatment in each group,and the improvement was more notable in the treatment group than in the control group,showing statistical significance(P＜0.05).There was no significant difference between the two groups when comparing the incidence rate of"long COVID syndrome"(P＞0.05).The between-group difference in the secondary infection of COVID-19 was statistically insignificant(P＞0.05).The safety rating was satisfactory in both groups.Conclusion On the basis of oral administration of Chinese patent medicine,needle-warming moxibustion plus blood-letting and cupping can produce significant clinical efficacy in treating patients with mild COVID-19 infection with a high safety rating.
Needle warming therapyBlood-letting puncturing and cuppingAcupuncture medication combinedCOVID-19DefervescenceCough
万方数据
维普
